{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:59:01Z","timestamp":1768287541460,"version":"3.49.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ek0109613h0001"],"award-info":[{"award-number":["22ek0109613h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.toxicon.2023.107264","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T15:20:03Z","timestamp":1693408803000},"page":"107264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A look at the future\u2014new BoNTs and delivery systems in development: What it could mean in the clinic"],"prefix":"10.1016","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0165-2671","authenticated-orcid":false,"given":"Ryuji","family":"Kaji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2023.107264_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.914486","article-title":"OnabotulinumtoxinA dosing, disease severity, and treatment benefit in patients with cervical dystonia: a cohort analysis from CD PROBE","volume":"13","author":"Agarwal","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.toxicon.2023.107264_bib2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.toxicon.2010.07.015","article-title":"Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses","volume":"56","author":"Akaike","year":"2010","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2023.107264_bib3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1113\/jphysiol.2012.242131","article-title":"Transsynaptic inhibition of spinal transmission by A2 botulinum toxin","volume":"591","author":"Akaike","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.toxicon.2023.107264_bib4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmb.2006.07.040","article-title":"A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4","volume":"362","author":"Arndt","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.toxicon.2023.107264_bib5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1468-1331.2005.01095.x","article-title":"The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences","volume":"12","author":"Barnes","year":"2005","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2023.107264_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12732","article-title":"Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A","volume":"505","author":"Benoit","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.toxicon.2023.107264_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/srep43588","article-title":"Crystal structure of the BoNT\/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C","volume":"7","author":"Benoit","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxicon.2023.107264_bib8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxicon.2023.107264_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.abf5972","article-title":"Phage-assisted evolution of botulinum neurotoxin proteases with reprogrammed specificity","volume":"371","author":"Blum","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.toxicon.2023.107264_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13120834","article-title":"New modified recombinant botulinum neurotoxin type F with enhanced potency","volume":"13","author":"Burgin","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.toxicon.2023.107264_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.toxicon.2008.12.026","article-title":"Central effects of tetanus and botulinum neurotoxins","volume":"54","author":"Caleo","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2023.107264_bib13","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1523\/JNEUROSCI.0294-18.2018","article-title":"Transynaptic action of botulinum neurotoxin type A at central cholinergic boutons","volume":"38","author":"Caleo","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.toxicon.2023.107264_bib14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.20344\/amp.11503","article-title":"Contralateral upper limb weakness following botulinum toxin A injection for poststroke spasticity","volume":"33","author":"Camoes-Barbosa","year":"2020","journal-title":"Acta Med. Port."},{"key":"10.1016\/j.toxicon.2023.107264_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13010058","article-title":"Botulinum toxin: an update on pharmacology and newer products in development","volume":"13","author":"Choudhury","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2023.107264_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2005.06.011","article-title":"Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases","volume":"53","author":"Cote","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxicon.2023.107264_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00702-015-1453-x","article-title":"Strategies for treatment of dystonia","volume":"123","author":"Dressler","year":"2016","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.toxicon.2023.107264_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00702-016-1641-3","article-title":"Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results","volume":"124","author":"Dressler","year":"2017","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.toxicon.2023.107264_bib20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00415-022-11424-0","article-title":"Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations","volume":"270","author":"Dressler","year":"2023","journal-title":"J. Neurol."},{"issue":"Suppl. 8","key":"10.1016\/j.toxicon.2023.107264_bib21","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1002\/mds.20010","article-title":"Different types of botulinum toxin in humans","volume":"19","author":"Eleopra","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2023.107264_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3940(98)00775-7","article-title":"Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans","volume":"256","author":"Eleopra","year":"1998","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.toxicon.2023.107264_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(97)13448-6","article-title":"Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human","volume":"224","author":"Eleopra","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.toxicon.2023.107264_bib24","first-page":"960","article-title":"OnabotulinumtoxinA for lower limb spasticity: guidance from a delphi panel approach","volume":"9","author":"Esquenazi","year":"2017","journal-title":"Pharm. Manag. PM R"},{"key":"10.1016\/j.toxicon.2023.107264_bib25","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.apmr.2021.06.008","article-title":"Real-world adherence to OnabotulinumtoxinA treatment for spasticity: insights from the ASPIRE study","volume":"102","author":"Esquenazi","year":"2021","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.toxicon.2023.107264_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.toxicon.2017.05.001","article-title":"Botulinum toxin type A reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain","volume":"133","author":"Fan","year":"2017","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2023.107264_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10050208","article-title":"The expanding therapeutic utility of botulinum neurotoxins","volume":"10","author":"Fonfria","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15010060","article-title":"Clinical immunogenicity of DaxibotulinumtoxinA for injection in glabellar lines: pooled data from the SAKURA phase 3 trials","volume":"15","author":"Gallagher","year":"2023","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10070268","article-title":"Light chain diversity among the botulinum neurotoxins","volume":"10","author":"Gardner","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib30","article-title":"Structural features of Clostridium botulinum neurotoxin subtype A2 cell binding domain","volume":"14","author":"Gregory","year":"2022","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10040153","article-title":"Crystal structure of botulinum neurotoxin A2 in complex with the human protein receptor SV2C reveals plasticity in receptor binding","volume":"10","author":"Gustafsson","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40257-019-00482-2","article-title":"Updates on botulinum neurotoxins in dermatology","volume":"21","author":"Hanna","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.toxicon.2023.107264_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/164_2019_311","article-title":"Manufacturing and clinical formulations of botulinum neurotoxins","volume":"263","author":"Hasan","year":"2020","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.toxicon.2023.107264_bib34","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00415-022-11395-2","article-title":"Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin","volume":"270","author":"Hefter","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.toxicon.2023.107264_bib35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ccc.2005.06.008","article-title":"Botulinum toxin","volume":"21","author":"Horowitz","year":"2005","journal-title":"Crit. Care Clin."},{"key":"10.1016\/j.toxicon.2023.107264_bib36","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00438-014-0887-4","article-title":"Complete nucleotide sequence of a plasmid containing the botulinum neurotoxin gene in Clostridium botulinum type B strain 111 isolated from an infant patient in Japan","volume":"289","author":"Hosomi","year":"2014","journal-title":"Mol. Genet. Genom."},{"key":"10.1016\/j.toxicon.2023.107264_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.toxicon.2017.09.004","article-title":"Longitudinal studies of botulinum toxin in cervical dystonia: why do patients discontinue therapy?","volume":"147","author":"Jinnah","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2023.107264_bib38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1113\/jphysiol.2012.246322","article-title":"Direct central action of intramuscularly injected botulinum toxin: is it harmful or beneficial?","volume":"591","author":"Kaji","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.toxicon.2023.107264_bib39","first-page":"510","article-title":"Comparative study of spread of A1 and A2 subtypes of botulinum toxin preparations for blepharospasm: proof-ofconcept randomized controlled trial","volume":"30","author":"Kaji","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2023.107264_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14110739","article-title":"A pilot study of A2NTX, a novel low-molecular-weight neurotoxin derived from subtype A2 for post-stroke lower limb spasticity: comparison with OnabotulinumtoxinA","volume":"14","author":"Kaji","year":"2022","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib41","first-page":"6","article-title":"The functional independence measure: a new tool for rehabilitation","volume":"1","author":"Keith","year":"1987","journal-title":"Adv. Clin. Rehabil."},{"key":"10.1016\/j.toxicon.2023.107264_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00403-011-1179-z","article-title":"Comparison of the spread of three botulinum toxin type A preparations","volume":"304","author":"Kerscher","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.toxicon.2023.107264_bib43","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/toxins7072435","article-title":"Botulinum toxin as a pain killer: players and actions in antinociception","volume":"7","author":"Kim","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib44","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/1348-0421.12796","article-title":"Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells","volume":"64","author":"Kohda","year":"2020","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.toxicon.2023.107264_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fneur.2014.00098","article-title":"Spinal central effects of peripherally applied botulinum neurotoxin A in comparison between its subtypes A1 and A2","volume":"5","author":"Koizumi","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.toxicon.2023.107264_bib46","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1128\/IAI.66.10.4811-4816.1998","article-title":"Characterization of Clostridium botulinum type B neurotoxin associated with infant botulism in Japan","volume":"66","author":"Kozaki","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.toxicon.2023.107264_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00795-16","article-title":"Entry of botulinum neurotoxin subtypes A1 and A2 into neurons","volume":"85","author":"Kroken","year":"2017","journal-title":"Infect. Immun."},{"key":"10.1016\/j.toxicon.2023.107264_bib48","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.clinph.2019.02.007","article-title":"Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT\/A and B non-responding patients","volume":"130","author":"Kutschenko","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.toxicon.2023.107264_bib49","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1097\/SAP.0000000000003367","article-title":"Selective myectomy and myotomy in situ for the management of refractory blepharospasm in meige syndrome","volume":"90","author":"Lai","year":"2023","journal-title":"Ann. Plast. Surg."},{"key":"10.1016\/j.toxicon.2023.107264_bib50","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1126\/science.103.2681.613","article-title":"The purification and crystallization of Clostridium botulinum type A toxin","volume":"103","author":"Lamanna","year":"1946","journal-title":"Science"},{"key":"10.1016\/j.toxicon.2023.107264_bib51","article-title":"Transformation of a metal chelate into a \"catch and anchor\" inhibitor of botulinum A protease","volume":"24","author":"Lin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.toxicon.2023.107264_bib52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.parkreldis.2019.02.020","article-title":"Remission in dystonia - systematic review of the literature and meta-analysis","volume":"66","author":"Mainka","year":"2019","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.toxicon.2023.107264_bib53","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1113\/jphysiol.2012.239178","article-title":"Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A","volume":"591","author":"Marchand-Pauvert","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.toxicon.2023.107264_bib54","series-title":"Structure and Activity of Botulinum Neurotoxin X","author":"Martinez-Carranza","year":"2023"},{"key":"10.1016\/j.toxicon.2023.107264_bib55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bph.14846","article-title":"Evidence for central antispastic effect of botulinum toxin type A","volume":"177","author":"Matak","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.toxicon.2023.107264_bib56","first-page":"137","article-title":"Distant OnabotulinumtoxinA spread after cosmetic dosing to facial rhytides","volume":"17","author":"McGuinn","year":"2019","journal-title":"Skinmed"},{"key":"10.1016\/j.toxicon.2023.107264_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd7789","article-title":"Neuronal delivery of antibodies has therapeutic effects in animal models of botulism","volume":"13","author":"McNutt","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.toxicon.2023.107264_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0333102420970507","article-title":"Combined onabotulinumtoxinA\/atogepant treatment blocks activation\/sensitization of high-threshold and wide-dynamic range neurons","volume":"41","author":"Melo-Carrillo","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2023.107264_bib59","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1212\/WNL.45.3.506","article-title":"Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study","volume":"45","author":"Mezaki","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2023.107264_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15020123","article-title":"Characterization of serotype CD mosaic botulinum neurotoxin in comparison with serotype C and A","volume":"15","author":"Miyashita","year":"2023","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107264_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz4197","article-title":"Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism","volume":"13","author":"Miyashita","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.toxicon.2023.107264_bib62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/dmcn.13286","article-title":"Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase","volume":"59","author":"Montastruc","year":"2017","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.toxicon.2023.107264_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221141683","article-title":"OnabotulinumtoxinA effects on trigeminal nociceptors","volume":"43","author":"Moore","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2023.107264_bib64","series-title":"Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6","author":"Moritz","year":"2018"},{"key":"10.1016\/j.toxicon.2023.107264_bib65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.toxicon.2019.06.004","article-title":"Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis","volume":"167","author":"Moritz","year":"2019","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2023.107264_bib66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.toxicon.2013.12.012","article-title":"Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals","volume":"81","author":"Mukai","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2023.107264_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00089-18","article-title":"The light chain defines the duration of action of botulinum toxin serotype A subtypes","volume":"9","author":"Pellett","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.toxicon.2023.107264_bib68","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbrc.2011.01.093","article-title":"Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A","volume":"405","author":"Pellett","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.toxicon.2023.107264_bib69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.toxicon.2015.06.021","article-title":"In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5","volume":"107","author":"Pellett","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2023.107264_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.857","article-title":"Recombinant botulinum neurotoxin serotype A1 in vivo characterization","volume":"9","author":"Perier","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.toxicon.2023.107264_bib71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.febslet.2010.11.045","article-title":"Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1","volume":"585","author":"Pier","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.toxicon.2023.107264_bib72","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2340\/00015555-2093","article-title":"Regional diffusion of botulinum toxin in facial muscles: a randomised double-blind study and a consideration for clinical studies with split-face design","volume":"95","author":"Punga","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.toxicon.2023.107264_bib73","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/WNF.0b013e31815cba8a","article-title":"Undesirable distant effects following botulinum toxin type a injection","volume":"31","author":"Roche","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxicon.2023.107264_bib74","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8","article-title":"Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection","volume":"19","author":"Rosales","year":"1996","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.toxicon.2023.107264_bib75","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0168-1605(90)90016-X","article-title":"Distinct characters of Clostridium botulinum type A strains and their toxin associated with infant botulism in Japan","volume":"11","author":"Sakaguchi","year":"1990","journal-title":"Int. J. Food Microbiol."},{"key":"10.1016\/j.toxicon.2023.107264_bib76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5603\/PJNNS.a2021.0029","article-title":"Botulinum neurotoxin in cervical dystonia revisited - recent advances and unanswered questions","volume":"55","author":"Slawek","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.toxicon.2023.107264_bib77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.49.1.189","article-title":"Human response to botulinum toxin injection: type B compared with type A","volume":"49","author":"Sloop","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2023.107264_bib78","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1128\/IAI.73.9.5450-5457.2005","article-title":"Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization","volume":"73","author":"Smith","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.toxicon.2023.107264_bib79","first-page":"2091","article-title":"Overview of DaxibotulinumtoxinA for injection: a novel formulation of botulinum toxin","volume":"81","author":"Solish","year":"2021","journal-title":"Type A. Drugs"},{"key":"10.1016\/j.toxicon.2023.107264_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911626","article-title":"Lasting peripheral and central effects of botulinum toxin type A on experimental muscle hypertonia in rats","volume":"23","author":"Sostaric","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.toxicon.2023.107264_bib81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2020_351","article-title":"Novel native and engineered botulinum neurotoxins","volume":"263","author":"Steward","year":"2021","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.toxicon.2023.107264_bib82","article-title":"Clinical safety and tolerability of A2NTX, a novel low-molecular-weight neurotoxin derived from botulinum neurotoxin subtype A2","volume":"13","author":"Takeuchi","year":"2021","journal-title":"Comparison with Subtype A1 Toxins. Toxins (Basel"},{"key":"10.1016\/j.toxicon.2023.107264_bib83","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1254\/jphs.11121FP","article-title":"Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats","volume":"117","author":"Torii","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.toxicon.2023.107264_bib84","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.toxicon.2013.11.006","article-title":"Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies","volume":"77","author":"Torii","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2023.107264_bib85","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.toxicon.2010.10.009","article-title":"Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test","volume":"57","author":"Torii","year":"2011","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2023.107264_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/srep42923","article-title":"Engineering botulinum neurotoxin C1 as a molecular vehicle for intra-neuronal drug delivery","volume":"7","author":"Vazquez-Cintron","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxicon.2023.107264_bib87","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1128\/IAI.00536-13","article-title":"Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro","volume":"81","author":"Whitemarsh","year":"2013","journal-title":"Infect. Immun."},{"key":"10.1016\/j.toxicon.2023.107264_bib88","doi-asserted-by":"crossref","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","article-title":"Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study","volume":"142","author":"Yoelin","year":"2018","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2023.107264_bib89","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/jocd.14658","article-title":"Pivotal role of injection volume on sunken cheek prevention in masseter muscle BoNT-A injection: a cadaver study","volume":"21","author":"Yu","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.toxicon.2023.107264_bib90","article-title":"Identification and characterization of a novel botulinum neurotoxin","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010123002507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010123002507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:18:40Z","timestamp":1736363920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010123002507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":90,"alternative-id":["S0041010123002507"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2023.107264","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A look at the future\u2014new BoNTs and delivery systems in development: What it could mean in the clinic","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2023.107264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107264"}}